Linezolid Kabi Indications/Uses

Nosocomial Pneumonia: Linezolid Kabi is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Community-acquired Pneumonia: Linezolid Kabi is indicated for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Complicated Skin and Skin Structure Infections: Linezolid Kabi is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae. Linezolid Kabi has not been studied in the treatment of decubitus ulcers [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Vancomycin-resistant Enterococcus faecium Infections: Linezolid Kabi is indicated for the treatment of vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Limitations of Use: Linezolid Kabi is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [see Precautions].
The safety and efficacy of Linezolid Kabi given for longer than 28 days have not been evaluated in controlled clinical trials [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Linezolid Kabi and other antibacterial drugs, Linezolid Kabi should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.